Alkermes plc. Long-Term Debt, Maturity, Year Three
Alkermes plc. (ALKS) had Long-Term Debt, Maturity, Year Three of $45.25 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree · last filed 2026-07-28
- 2026-06-30: Long-Term Debt, Maturity, Year Three $45.25M.
- 2026-03-31: Long-Term Debt, Maturity, Year Three $45.25M.
| Period end | Long-Term Debt, Maturity, Year Three |
|---|---|
| 2026-06-30 | $45.25M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $45.25M 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |